Why do we lack an effective vaccine against herpes simplex virus infections?

Microbes and Infection

Volumn 2, Issue 8, 2000, Pages 973-978

  Deshpande, Shilpa P ^a   Kumaraguru, Udayasankar ^a   Rouse, Barry T ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Herpes simplex virus; Immune response; Vaccines

Indexed keywords

HERPES SIMPLEX VACCINE;

DRUG EFFICACY; DRUG RESEARCH; DRUG SENSITIVITY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOLOGICAL MEMORY; LYMPHOCYTE PROLIFERATION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS IMMUNITY;

DNA VIRUSES; HERPES; HERPESVIRIDAE; SIMPLEXVIRUS;

EID: 0033925360     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(00)00339-7     Document Type: Review

References (54)

1. Liesegang T.J., Melton L.J., Daly P.J., Ilstrup D.M. Epidemiology of ocular herpes simplex virus. Incidence in Rochester, Minn, 1950 through 1982. Arch Opthalmol. 107:1989;1155-1159.
2. Roizman B., Sears A.E. Fields B.N, Knipe D.M, Howley P.M. Field′s Virology. 1996;2231-2295 Lippincott-Raven, Philadelphia.
3. Glorioso J.C., Goins W.F., Schmidt M.C., Oligino T., Krisky D.M., Marconi P.C., Cavalcoli J.D., Ramakrishnan R., Poliani P.L., Fink D.J. Engineering herpes simplex virus vectors for human gene therapy. Adv. Pharmacol. 40:1997;103-136.
4. Daheshia M., Feldman L.T., Rouse B.T. Herpes simplex virus latency and the immune response. Curr. Opin. Microbiol. 1:1998;430-435.
5. Banks T.A., Rouse B.T. Herpesviruses - Immune escape artists? Clin. Infect. Dis. 14:1992;933-941.
6. + T lymphocytes. Cell. 77:1994;525-535.
7. Jennings S.R., Rice P.L., Kloszewski E.D., Anderson R.W., Thompson D.L., Tevethia S.S. Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. J. Virol. 56:1985;757-766.
8. Friedman H.M., Cohen G.H., Eisenberg R.J., Seidel C.A., Cines D.B. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 309:1994;633-635.
9. Raftery M.J., Behrens C.K., Miller A., Krammer P.H., Walczak H., Gunther S. Herpes simplex virus type 1 infection of activated cytotoxic T cells: induction of fratricide as a mechanism of viral immune evasion. J. Exp. M. 8:1999;1103-1113.
10. Salio M., Cella M., Suter M., Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 1999;3245-3253.
11. Whitley R.J. Fields B.N, Knipe D.M, Howley P.M. Field′s Virology. 1996;2297-2342 Lippincott-Raven, Philadelphia.
12. Montgomery R.I., Warner M.S., Lum B.J., Spear P.G. Herpes simplex virus -1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell. 87:1996;427-436.
13. Geraghty R.J., Krummenacher C., Cohen G.H., Eisenberg R.J., Spear P.G. Entry of alphaherpes viruses mediated by polio virus receptor related protein 1 and polio virus receptor. Science. 280:1998;1618-1620.
14. Logu A., Williamson A.R., Rozenshteyn R., Ranuro-Ibanez F., Simpson C.D., Burton D.R., Sanna P.P. Characterization of a type common human recombinant monoclonal antobody to herpes simplex virus with high therapeutic potential. J. Clin. Microbiol. 1998;3198-3204.
15. Miklosa Z., Sanna P.P., Cunnigham A.L. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J. Virol. 1999;5934-5944.
16. Shimeld C., Hill T.J., Blyth W.A., Easty D.I. Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limited spread of virus in the nervous system. J. Gen. Virol. 71:1990;681-687.
17. Daheshia M., Deshpande S., Chun S., Kuklin N.A., Rouse B.T. Resistance to herpetic stromal keratitis in immunized B cell deficient mice. Virology. 257:1999;168-176.
18. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. Role of mucosal immunity in the herpes simplex virus infection. J. Immunol. 160:1997;5998-6003.
19. Bernstein D.J., Stanberry L.R. Herpes simplex virus vaccines. Vaccine. 17:1999;1681-1689.
20. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73:1999;329-368.
21. Enquist L.W., Husak P.J., Banfield B.W., Smith G.A. Infection and spread of alphaherpesviruses in the nervous system. Adv. Virus Res. 51:1998;237-347.
22. Steiner I., Spivack J.G., Deshmane S.L., Ace C.I., Preston C.M., Fraser N.W. A simplex virus type -1 mutant containing a non transducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglion. J. Virol. 64:1999;1630-1638.
23. Margolis T.P., Sedarati F., Dobson A.T., Feldman L.T., Stevens J.G. Pathways of viral gene expression during acute neuronal infection with HSV-1. Virology. 189:1992;150-160.
24. Farrell M.J., Dobson A.T., Feldman L.T. Herpes simplex virus latency-associated transcripts is a stable intron. Proc. Natl. Acad. Sci. USA. 88:1991;790-794.
25. Mester J.C., Milligan G.N., Bernstein D.I. Stanberry L.R. Genital and neonatal herpes. 1996;49-91 John Wiley and Son Ltd.
26. Liu T., Tang Q., Hendricks R.L. Inflammatory inflitration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J. Virol. 1996;264-271.
27. Cantin E.M., Hinton D.R., Chen J., Openshaw H. Gamma interferon expression during acute and latent nervous system infection by herpes simplex type -1. J. Virol. 1995;4898-4905.
28. Kodukula P., Liu T., Rooijen N.V., Jager M.J., Hendricks R.L. Macrophage control of herpes simplex virus type 1 reactivation in the peripheral nervous system. J. Immunol. 162:1999;2895-2905.
29. Sciammas R., Kodukula P., Tang Q., Hendricks R.L., Bluestone J.A. T cell receptor gamma/delta cells protect mice from herpes simplex virus type1 induced lethal encephalitis. J. Exp. M. 185:1997;1969-1975.
30. Gebhardt B.M., Hill J.M. Cellular neuroimmunological responses to ocular herpes simplex virus infection. J. Neuroimmunol. 28:1990;227-236.
31. Thomas J., Gangappa S., Kanangat S., Rouse B.T. On the essential role of neutrophils in the immunopathological disease - herpetic stromal keratitis. J. Immunol. 158:1997;1383-1391.
32. Milligan G.N. Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J. Virol. 1999;6380-6386.
33. Daheshia M., Kanangat S., Rouse B.T. Production of key molecules by ocular neutrophils early after herpetic infection of the cornea. Exp. Eye Res. 67:1998;619-624.
34. Kanangat S., Thomas J., Gangappa S., Babu J.S., Rouse B.T. Herpes simplex virus type 1 mediated upregulation of IL 12 (p40) mRNA expression: implications in immunopathogenesis and protection. J. Immunol. 156:1996;1110-1116.
35. Biron C.A. Initial and innate responses to viral infections- pattern setting in immunity or disease. Curr. Opin. Microbiol. 2:1999;374-381.
36. Russel R.G., Naisisse M.P., Larsen H.S., Rouse B.T. Role of T lymphocytes in the pathogenesis of herpetic stromal keratitis. Invest. Ophthalmol. Vis. Sci. 25:1984;938-944.
37. Manickan E., Rouse B.T. Roles of different T cell subsets in control of herpes simplex virus infection determined by using T cell deficient mouse model. J. Virol. 69:1995;8178-8179.
38. Rouse B.T., Daheshia M., Schmid S.D. Cunningham M.W, Fujinami R.S. Herpes simplex virus and the immune response: A balance of powers. 2000;387-398 Lippincott Williams and Wilkins, Philadelphia.
39. Wallace M.E., Keating R., Heath W.R., Carbone F.R. The cytotoxic T cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J. Virol. 1999;7619-7626.
40. Blaney J.E., Nobusawa E., Brehm M.A., Bonneau R.H., Mylin L.M., Fu T., Kawaoka Y., Tevethia S. Immunization with a single major histocompatibility complex class I restricted cytotoxic T lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 1998;9567-9574.
41. Guidotti L.G., Chisari F.V. To kill or to cure: options in host defense against viral infection. Curr. Opin. Immunol. 8:1996;478-483.
42. Ghiasi H., Cai S., Slanina S., Nesburn A.B., Wechsler S.L. Non neutralizing antibody against the glycoprotein K of herpes simplex virus type 1 exacerbates nerpes simplex virus type 1 induced corneal scarring in various virus mouse strain combination. Invest. Opthal. Vis. Sci. 38:1997;1213-1221.
43. Parr E.L., Parr M.B. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 1997;8109-8115.
44. Parr M.B., Harrisman G.R., Parr E.L. Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Immunology. 95:1998;208-213.
45. Merriman H., Woods S., Winter C., Fahnlander A., Corey L. Secretary IgA antibody in servicovaginal secretions from women with genital infection due to herpes simplex virus. J. Infect. Dis. 149:1984;505-510.
46. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV 2 from recurrent genital lesions correlated with infiltration of HSV specific cytotoxic T lymphocytes. J. Clin. Invest. 101:1998;1500-1508.
47. Cunningham A.L., Turner R.R., Miller A.C., Pera M.F., Meryan T.C. Evolution of recurrent herpes simplex lesions: an immunohistochemical study. J. Clin. Invest. 75:1985;226-233.
48. Posavad C.M., Koelle D.M., Corey L. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nature M. 4:1998;381-382.
49. + cytotoxic T lymphocytes responses. Proc. Natl. Acad. Sci. USA. 94:1997;10289-10294.
50. Barber L.D., Parham P. The essence of epitopes. J. Exp. M. 180:1994;1191-1194.
51. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241-251.
52. Goldrath A.W., Bevan M.J. Selecting and maintaining a diverse T cell repertoire. Nature. 402:1999;255-262.
53. Kumarguru U., Rouse B.T. DNA vaccines for the prophylaxis and modulation of HSV infections. Exp. Opin. Invest. Drugs. 7:1998;219-224.
54. Gupitu A., Petersson M., O'DDonnell C.L., Williams K., Jindal S., Kiessling R., Welsh R.M. Immunization with a lymphocyte choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. M. 187:1998;685-691.